Sharecafe

A precision oncology company

Presenter - Daniel Tillett - Chief Scientific Officer & Executive Director - Race Oncology is a precision oncology company with a Phase II/III cancer drug called Bisantrene. The drug is a potent small molecule inhibitor of the Fat mass and obesity associated (FTO) protein.

Race Oncology (ASX: RAC) – Hidden Gems Webinar. Presenter – Daniel Tillett – Chief Scientific Officer & Executive Director – Race Oncology is a precision oncology company with a Phase II/III cancer drug called Bisantrene. The drug is a potent small molecule inhibitor of the Fat mass and obesity associated (FTO) protein.

Serving up fresh finance news, marker movers & expertise.
LinkedIn
Email
X

All Categories